The key growth driver for CytoSorbents is the US market, the report noted, with the company working to strengthen its resources by installing a cardiac surgery advisory board as well as recruiting a clinical management team to conduct a pivotal clinical trial. The analyst belives the company could be in a position to finalize the trial design and file an investigational drug exemption by the end of this year, in line with previous guidance.
H.C. Wainwright also highlighted the company's HemoDefend blood purification product, which functions by prolonging the life of old blood cells while keeping new blood fresh. The product has potential applications in transfusions, with results from a phase 3 trial expected later this month at the American Association of Blood Banks conference.
Partnership discussions are anticipated in the near future if positive results are yielded, wrote Ramakanth. "While our current model does not account for revenues from this product we view this as a potential upside," the analyst said.
The company has also simplified its capitalization structure, and is in the process of completing requirements to up list to an "as yet undisclosed" national exchange, which H.C. Wainwright believes can be completed by the end of 2014.
CytoSorbents' technology is based on biocompatible, highly porous polymer sorbent beads that are capable of extracting unwanted substances, such as drugs, dangerous chemicals, toxins, cytokines, free hemoglobin, and antibodies, from blood and other bodily fluids.
Already provided, but here is full report:
In the analyst report, the firm cited strong revenue growth, with CytoSorbents announcing preliminary third quarter sales yesterday of nearly $1 million, an increase of 50 percent compared to the second quarter of 2014 and more than 390 percent versus the same period last year. CytoSorbents (OTCBB:CTSO) rose on Wednesday after the critical care-focused company beat expectations with its preliminary third quarter results and had its buy rating reiterated by analysts at H.C. Wainwright, who said multiple growth drivers still remain.
Analyst Swayampakula Ramakanth reiterated his buy rating and 12-month price target of $1.00, on the continued belief the shares are undervalued. The company, which uses blood purification products to treat life threatening diseases, added 6.6 percent today to 27.4 cents.
In the analyst report, the firm cited strong revenue growth, with CytoSorbents announcing preliminary third quarter sales yesterday of nearly $1 million, an increase of 50 percent compared to the second quarter of 2014 and more than 390 percent versus the same period last year.
Based on the latest announcement, H.C. Wainwright expects sales to reach over $3 million for fiscal year 2014, better than its previous estimate of $2.56 million.
The analyst wrote that repeat orders from current customers and existing distributors were drivers for sales in the latest period, which H.C. Wainwright believes could continue into the fourth quarter and beyond based on continued growth in current markets and a potential launch in the Middle East.
Future sales are also expected to increase based on an increased sales force in Germany from 4 to 10 by year-end, and market expansion of certain distributors. H.C. Wainwright is projecting total revenues of nearly $8.15 million in fiscal year 2015.
Got price right but only half the volume. Oh well. Let's see what happens!
More on Tweet: Posted by Van Hipp: Chairman of the American Defense International, Inc. formerly Deputy Assistant Secretary of the US Army:
His website is www.vanhipp.com
This may be far fetched but we will see. Once people uncover this hidden play, as well as hidden ebola play, the volume will go crazy. My prediction:
5M shares today: .$26 price
10M shares tomorrow: $.33 price
16M shares Friday: $.45 price
May be wishful thinking but certainly not out of the question.
I hope I am right.
For those now interested in buying ion the dips. NOW is the time. I see $.50 very soon!
Chan touched on everything we needed. Go CTSO!!!
Could CytoSorb® Help?
The 2014 Ebola epidemic in West Africa, called an “international emergency” by the WHO, continues to grow and has already infected nearly 1,900 people, and claimed more than 1,000 lives. Epidemic is expected to continue throughout the year. Our Strategy for outreach:
• Government agencies such as USAMRIID (US Army Medical Research Institute of Infectious Diseases)
• Non-profit organizations
• Hospitals treating Ebola patients inside/outside of West Africa
Seems to me CTSO should become more visible as a potential devise that could be used to prevent cytokine storm and allow immune system time to work.
From Sepsis Alliance Website:
There is no treatment for Ebola at this point. People who have Ebola often develop sepsis, so treatment involves trying to keep them from going into septic shock and managing organ dysfunction, such as kidney shut down, dropping blood pressure, difficulty breathing, etc. According to the National Institutes of Health (NIH), those who die from Ebola usually die from shock, low blood pressure.
For those that forgot:
• Ebola is one of the most deadly viruses known with a very high mortality rate of 50-90% depending upon the strain, and very contagious (bodily fluids)
• Following an incubation phase of 2-21 days, has an abrupt onset of symptoms including high fever, chills, weakness and body pain, followed by more severe symptoms including diarrhea, cough, headache, and bleeding with vomiting of blood or blood in stool
• Patients typically die with time to death (from onset of symptoms) of 6-16 days. Culminates in a cytokine release syndrome
• Key to why Ebola is so deadly is its ability to evade the immune response, resulting in advanced infection that culminates in cytokine storm, deadly inflammation, and multiple organ failure
•Initial suppression of the anti-viral cytokine immune response allows rampant viral replication
•Release of soluble viral glycoproteins (sGP) that interfere with white blood cell activation and act as a decoy so that antibodies cannot neutralize the virus
• CytoSorb may have benefit by reducing cytokine storm and sGP, buying time for the immune system to kill the virus
No way I short now. Long is Up from here. Gambled and went long on Tuesday. I did the same with SPLK and VEEV as well. The strategy has being great!
Nothing new, but at least its publicity.
Google Today's Medical Developments Cytosorb
This looks to us like it will translate in to a steady, modest growth trajectory, with no impending near-term milestone.
As for approval in the U.S., a small pilot trial is underway that is funded by the U.S. Air Force in trauma and rhabdomyolysis (muscle-crushing trauma). Although anecdotal results show that CytoSorb is saving lives in Europe, the company must do a trial in the U.S. before the FDA considers the product for approval. Importantly, the FDA has reviewed the safety date from the European trial and given CytoSorbents an investigational device exemption approval to conduct the Air Force trial. This application is one possible path to U.S. approval. The company also plans to commence a pivotal trial in sepsis, cardiac surgery or perhaps other indications by the end of this year that could lead to U.S. approval.
I project an organic ramp-up in growth as CytoSorbents expands its sales force, which is small now because it's a small company, with a $72M market cap. It appears as though CytoSorbents will achieve $1M in trailing 12-month sales in this quarter, with sales mainly in just three countries—Germany, Austria and the United Kingdom.